Esophageal Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against esophageal cancer and guarantee the finest results for our customers all over the world.

Esophageal Cancer

Esophageal cancer is a cancer arising from the esophagus, which is a food pipe runs between the throat and stomach. The two main sub-types of the disease are esophageal squamous-cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC is more common in developing countries while EAC is more common in developed countries. Adenocarcinoma arises from the lower third of the esophagus, where they usually have been transformed into intestinal cell types (a condition known as Barrett’s esophagus). Reasons for squamous cell types include alcohol, tobacco, very hot drinks, chewing betel nuts and poor diets. The most common causes of adenocarcinoma type include obesity, smoking, and acid reflux. Some of the less common types include squamous cell carcinomas from esophageal epithelial cells. Symptoms usually include weight loss and dysphagia. Other symptoms may include pain when swallowing, hoarseness, swollen lymph nodes ("glands") around the collarbone, dry cough and vomiting blood.

Therapeutic Vaccines for Esophageal Cancer

Dendritic cells (DC) are the major antigen presenting cells in mammalians. Immunotherapy using DC presenting tumor antigens has been considered as a promising tumor biological treatment and has demonstrated good safety and effectiveness against esophageal cancer. DC can present heat shock proteins (HSP) receptors, which increases the antigen-loading efficiency and activates stronger cytotoxic lymphocyte response. Studies found that heat shock treatment might induce a high expression of HSP and tumor-related antigens in tumor cells, and DC loaded with these tumor cells could induce even stronger antitumor immune response.

The relative cancer tissue specificity of certain cell surface antigens also opens the door to design vaccines based against these antigens. A phase I clinical trial was carried out in advanced esophageal cancer patients treated with anti-MAGE-A4 vaccine. Of the 13 esophageal cancer patients who completed one vaccination cycle, 3 patients responded and the survival rate was significantly improved. Other preliminary anti-esophageal cancer vaccine trials reported success with an anti-NY-ESO1 vaccine and with a genetically engineered multi-epitope vaccine. Currently, there are no open and actively recruiting clinical trials on esophageal cancer vaccines. However, several trials have reached accrual, and the final results are pending.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the esophageal cancer vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.